Abstract:This study was purposed to investigate the B cell-activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) levels in bone marrow, and the BAFF receptor expression level on B cells in multiple myeloma (MM) patients, in order to explore the characteristics of B cells in bone marrow of MM patients. MM patients were studied before treatment (newly diagnosed group, 19 patients) and after treatment with improvement (stable group, 17 patients), 10 non-hematologic patients were selected as control (control group). The BAFF receptors (BAFF-R) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) on B cell (CD19(+)), naive B cell (CD19(+)IgD(+)) and memory B cell (CD19(+)CD27(+)) of bone marrow in all groups were detected by flow cytometry. The BAFF, APRIL level in bone marrow supernatant were tested with ELISA. The results showed that the BAFF-R expression level on CD19(+) cells in newly diagnosed group were higher than that in stable group and control group; there was no significant difference between the BAFF-R expression level on CD19(+)IgD(+) cells in newly diagnosed group and stable group, but BAFF-R expression level on CD19(+)IgD(+) cells in newly diagnosed group was higher than that in control group; the BAFF-R expression level on CD19(+)CD27(+) cells in newly group was higher than that in stable group and control group; there was no significant difference between the BAFF-R expression level on CD19(+) cells, CD19(+)IgD(+) cells or CD19(+)CD27(+) cells in stable group and control group. There was no significant difference among the TACI expression level on CD19(+) cells, CD19(+)IgD(+) cells or CD19(+)CD27(+) cells in newly diagnosed group, stable group and control group. The bone marrow supernatant BAFF level in newly diagnosed group was higher than that in stable group and control group, but there was no significant difference between stable group and control group. There was no significant difference among the bone marrow TACI levels in newly diagnosed group, stable group and control group. It is concluded that both the bone marrow BAFF level and the BAFF-R expression level on CD19(+) cell, CD19(+)IgD(+) cells and CD19(+)CD27(+) cells in MM patients increase, which may help to stimulate B cells, thereby may relate with to MM pathogenesis.

BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses

BAFF Binding to T Cell-Expressed BAFF-R Promotes Follicular Helper T Cell Proliferation and GC B Cell Responses

BAFF promotes follicular helper T cell development and germinal center formation through BR3 signal

PD-L1-expressing B cells promote murine breast cancer development and mediate response to anti-PD-L1 immune checkpoint inhibitor.

Abstract 3978: B-cell activating factor (BAFF) enhances antitumor immunity

BAFF Inhibits Autophagy Promoting Cell Proliferation and Survival by Activating Ca2+-CaMKII-dependent Akt/mTOR Signaling Pathway in Normal and Neoplastic B-lymphoid Cells.

Contributions of each of the BAFF receptors to the lymphocyte profiles in C57BL/6 mice

IL-2, IL-4, IFN-γ or TNF-α Enhances BAFF-stimulated Cell Viability and Survival by Activating Erk1/2 and S6K1 Pathways in Neoplastic B-lymphoid Cells

Cutting Edge: Novel Function of B Cell-Activating Factor in the Induction of IL-10–Producing Regulatory B Cells

The Function of BAFF on T Helper Cells in Autoimmunity.

Current status of BAFF targeting immunotherapy in B-cell neoplasm

The Role BAFF and BAFF Receptors in Macrophage Induced Drug Resistance of Multiple Myeloma

BAFF Induces Spleen CD4+ T Cell Proliferation by Down-Regulating Phosphorylation of FOXO3A and Activates Cyclin D2 and D3 Expression

BFAR Coordinates TGFβ Signaling to Modulate Th9-mediated Cancer Immunotherapy

BAFF activates Erk1/2 promoting cell proliferation and survival by Ca 2+-CaMKII-dependent inhibition of PP2A in normal and neoplastic B-lymphoid cells

BAFF maintains T-cell survival by inducing OPN expression in B cells

B cell activating factor (BAFF) selects IL-10−B cells over IL-10+B cells during inflammatory responses

The Unknown Aspect of BAFF: Inducing IL-35 Production by a CD5+CD1dhiFcγRIIbhi Regulatory B-Cell Subset in Lupus.

BAFF suppresses IL-15 expression in B cells.

TNFR-Associated Factor-3 is Associated with BAFF-R and Negatively Regulates BAFF-R-Mediated NF-κB Activation and IL-10 Production

[BAFF Level in Bone Marrow and Expression of BAFF Receptor on B Cells in Multiple Myeloma Patients].